March 2008, Vol 1, No 2

In a small, intimate room in a tired old mansion serving as a Connecticut prep school in 1966, a gentle giant of learning listened intently to a youth in his class extol Ayn Rand's theory of Objectivism. It was English class, and Joseph T. Sunega, known time out of mind to the student body as Sunny Joe for his bright eyes drooping at half mast in a perpetual Celtic half dream, dropped a quiet bombshell on the boy and the class.

The goal of changing the way patent applications are filed and pursued is to stop the frenetic dance that companies must perform to maximize the period of patent protection.

Robert Henry: By way of introduction, Gary, give us the basic direction that you would like to take on today's subject—the high costs of biologics—whether your focus is on the benefit design structures that are going to be fashioned in response to the cost of biologics or elsewhere.

Value-Based Benefit— A Joint Effort

The current explosion in the science that supports discovery platforms and clinical development activities places a particular emphasis on the importance of integrating knowledge across a spectrum of interests and perspectives extending from the laboratory to the pharmacy. These efforts are driven by the increases in prevalence of chronic illnesses, the associated direct and indirect costs, and, for some indications, the rapid infusion/diffusion of innovative therapy into practice.

AHDB Stakeholder Perspective

Incidence, Prevalence, and Mortality

AHDB Stakeholder Perspective

Late in 2007, the U.S. Food and Drug Administration (FDA) held a public meeting chaired by Dr. Randall Lutter, Deputy Commissioner for Policy, and Dr. Douglas Throckmorton, Deputy Director for the Center for Drug Evaluation and Research, to discern the prevailing thought on the possibility of developing a behind-the-counter (BTC) status for drug access in the United States. Similar to over-the-counter (OTC) status, BTC would allow a patient to access medications at the pharmacy without seeing a doctor.

Capitol Hill Watch | Senate Finance Committee Bans American Medical Association From Medicare Reform Bill Talks

The Senate Finance Committee has banned the American Medical Association (AMA) from discussions about an upcoming Medicare package that would stop a 10% cut to physician fees, according to a Democratic aide, CongressDaily reports. The cuts will go into effect on July 1 unless Congress intervenes (Johnson, CongressDaily, 2/15).

The National Asthma Education and Prevention Program (NAEPP) released updated clinical guidelines for the diagnosis and management of asthma on August 29, 2007.

These guidelines are the most comprehensive updates in almost a decade and include recommendations for childhood asthma (expanded section), new guidance on medications, patient education in settings beyond the physician's office, and advice for controlling environmental factors that can cause asthma symptoms.

Results 1 - 8 of 8
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME